A novel series of indazole-/indole-based glucagon receptor antagonists

Bioorg Med Chem Lett. 2015 Oct 1;25(19):4143-7. doi: 10.1016/j.bmcl.2015.08.015. Epub 2015 Aug 8.

Abstract

A novel, potent series of glucagon receptor antagonists (GRAs) was discovered. These indazole- and indole-based compounds were designed on an earlier pyrazole-based GRA lead MK-0893. Structure-activity relationship (SAR) studies were focused on the C3 and C6 positions of the indazole core, as well as the benzylic position on the N-1 of indazole. Multiple potent GRAs were identified with excellent in vitro profiles and good pharmacokinetics in rat. Among them, GRA 16d was found to be orally active in blunting glucagon induced glucose excursion in an acute glucagon challenge model in glucagon receptor humanized (hGCGR) mice at 1, 3 and 10mg/kg (mpk), and significantly lowered acute glucose levels in hGCGR ob/ob mice at 3 mpk dose.

Keywords: Diabetes; Glucagon receptor antagonist; Glucose lowering; Indazole; Indole.

MeSH terms

  • Animals
  • CHO Cells
  • Cricetulus
  • Dose-Response Relationship, Drug
  • Humans
  • Indazoles / chemistry*
  • Indazoles / pharmacology*
  • Indoles / chemistry*
  • Indoles / pharmacology*
  • Mice
  • Mice, Obese
  • Molecular Structure
  • Rats
  • Receptors, Glucagon / antagonists & inhibitors*
  • Structure-Activity Relationship

Substances

  • Indazoles
  • Indoles
  • Receptors, Glucagon